Cancer therapeutics, immuno-oncology, and biotech innovation by Bicara Therapeutics

  • Hanna Syniavska
  • 17.11.2026
Ficerafusp alfa aims to enhance tumor targeting, says Bicara Therapeutics
Bicara Therapeutics has unveiled details of Ficerafusp alfa, a therapy designed to address inadequate tumor penetration in solid tumors, such as head and neck squamous cell carcinoma (HNSCC). The ...
  • Yaroslav Dmytrenko
  • 09.11.2026
Bicara Therapeutics posts Q3 2026 results and advances FORTIFI-HN01 trial enrollment
Bicara Therapeutics announced its financial results for the third quarter of 2026 and provided a business update on its operations. The company reported substantial enrollment progress in the ...
  • Mykhailo Ihnatenko
  • 02.11.2026
Bicara Therapeutics schedules financial results announcement and business update for November 9
Bicara Therapeutics will announce its third quarter 2026 financial results and provide a business update on Monday, November 9. The company will also host a conference call for investors at 8:30 ...
  • Ksenia Gerey
  • 20.10.2026
Bicara Therapeutics starts FORTIFI-FLEX trial for HPV-negative head and neck cancer
Bicara Therapeutics has launched its FORTIFI-FLEX clinical trial to evaluate a new dosing approach for patients with recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. ...
  • Oleg Tkachenko
  • 11.08.2026
Leadership transition positions Bicara Therapeutics Inc. for pivotal trial advancement
Bicara Therapeutics Inc. announced its financial results for the second quarter of 2026, highlighting notable changes in company leadership and a strategic shift to accelerate its operational ...
  • Elena Nikulina
  • 04.08.2026
Bicara Therapeutics Inc. to announce Q2 2026 results and host conference call August 11
Bicara Therapeutics Inc. will release its financial results for the second quarter of 2026 and provide a business update on Tuesday, August 11. The company will follow the announcement with a ...
  • Eugene Komchuk
  • 28.07.2026
Bicara Therapeutics Inc. appoints Jeremy Bender and Christy Oliger to board of directors
Bicara Therapeutics Inc. has named Jeremy Bender, Ph.D., MBA, and Christy Oliger to its Board of Directors, strengthening its leadership with more than 50 years of combined biopharma experience. ...
  • Igor Krasulya
  • 17.06.2026
Bicara Therapeutics Inc. appoints Chris Sarchi as Chief Commercial Officer to drive commercial growth
Bicara Therapeutics Inc. has appointed Chris Sarchi as Chief Commercial Officer as it evolves into a commercial-stage company. Sarchi brings significant experience in guiding oncology businesses ...
  • Yulia Slavina
  • 12.06.2026
Bicara Therapeutics Inc. joins ACS CAN in efforts to shape evidence-based cancer policies
Bicara Therapeutics Inc. participated in a Research Breakfast hosted by ACS CAN, underlining its alignment with advocates of evidence-based cancer policy. The company reiterated its dedication ...
  • Andrey Mastykin
  • 08.06.2026
Bicara Therapeutics Inc. presents three year Phase 1b results for ficerafusp alfa combination in HPV negative HNSCC
Bicara Therapeutics Inc. released three year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab in first line recurrent or metastatic HPV negative head and ...
  • Elena Nikulina
  • 28.05.2026
Bicara Therapeutics Inc. presents breakthrough in EGFR-targeted therapy for HPV-negative HNSCC
Bicara Therapeutics Inc. has announced the development of Ficerafusp alfa, the first and only EGFR-directed antibody fused to a TGF-beta ligand trap, engineered for overcoming clinical challenges ...
  • Parshwa Turakhiya
  • 26.05.2026
Bicara Therapeutics Inc. launches FORTIFI clinical trial targeting 1L R/M HPV negative HNSCC patients
Bicara Therapeutics Inc. has initiated the FORTIFI clinical trial aimed at addressing a significant unmet medical need in first-line recurrent or metastatic HPV-negative head and neck squamous ...